RxDoctor Payments Data

Kelly Timmer

Family · Great Falls, MTNPI 1669473526

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,500 of the $2,477 with a category attached, or 60.6%. Sebela Women's Health Inc. accounts for 60.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $1,665 and has fallen 97.0% since, to $50 in 2025. Among family clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,477in general payments, 2019–2025

Across 28 payments — averaging $88.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sebela Women's Health Inc.$2K
  • AbbVie$296
  • Amgen$216
  • AstraZeneca$208
  • Novo Nordisk$68
  • Astellas Pharma US Inc$46
  • plus $143 from 7 others

What the payments were for

  • Consulting fees$1,50061%
  • Food & beverage$95439%
  • Education$231%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,477 in reported general payments places this provider in the 90th percentile of 481 family providers in Montana.

See all family providers in Montana

Medicare billing

Part B allowed, 2024
$7,196
Medicare patients
55
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide11$6,156
ProgesteroneProgesterone, Micronized28$623
Clobetasol Propionate19$572
ValacyclovirValacyclovir Hcl14$558
Bupropion XlBupropion Hcl27$499
Estradiol11$494
Simvastatin15$216
Levothyroxine Sodium26$122
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide11$75
Omeprazole17$68
Trazodone Hcl15$62
Citalopram HbrCitalopram Hydrobromide21$33
Alprazolam12$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$296$6,15611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 family providers in Montana.

Other family in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →